IN THE CLAIMS

Please amend claims 24, 26, 38, 63, 65 and 67 as follows:

12 24. (Three Times Amended) The compound according to claim 1 38, wherein said compound is a compound of formula Ih:

E1

T1310



and is selected from any one of the following compounds:

T1311

cpd #	Structure	Cpd #	Structure
401		407	
402		408	

E

131

cpd #	Structure	Cpd #	Structure
403		409	
404		410	
405		411	

E'

E

132

cpd #	Structure	Cpd #	Structure
406			

E1

E2

26. (Twice Amended) A method of treating inflammatory diseases, autoimmune diseases, destructive bone disorders, infectious diseases, neurodegenerative diseases, reperfusion/ischemia in stroke, myocardial ischemia, renal ischemia, heart attacks, angiogenic disorders, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin-induced platelet aggregation or conditions associated with prostaglandin endoperoxide synthase-2 in a patient, said method comprising administering to said patient a composition according to claim 25.

E3

T1330

38. (Three Times Amended) A compound of the formula:



(If)

or



(Ih)

wherein:

each of Q_1 and Q_2 is independently selected from 5-6 membered aromatic carbocyclic or heterocyclic ring systems, or 8-10 membered bicyclic ring systems consisting of aromatic carbocyclic rings, aromatic heterocyclic rings or a combination of an aromatic carbocyclic ring and an aromatic heterocyclic ring;

E

Q_1 is substituted with 1 to 4 substituents, independently selected from halo; C_1-C_3 alkyl optionally substituted with NR'_2, OR', CO_2R' or $CONR'_2$; O-(C_1-C_3)-alkyl optionally substituted with NR'_2, OR', CO_2R' or $CONR'_2$; NR'_2; OCF_3; CF_3; NO_2; CO_2R'; CONHR'; SR'; $S(O_2)N(R')_2$; SCF_3; CN; $N(R')C(O)R^4$; $N(R')C(O)OR^4$; $N(R')C(O)C(O)R^4$; $N(R')S(O_2)R^4$; $N(R')R^4$; $N(R^4)_2$; OR^4; $OC(O)R^4$; $OP(O)_3H_2$; or N=CH-$N(R')_2$;

Q_2 is optionally substituted with up to 4 substituents, independently selected from halo; CH=N-OH; CH=O; C_1-C_3 straight or branched alkyl optionally substituted with NR'_2, OR', CO_2R', $S(O_2)N(R')_2$, N=CH-$N(R')_2$, R^3, NH–CH_3, $NHCH_2CH_2OH$, $NHCH_2CH(OH)CH_2OH$, $CH_2OCH_2OCH_3$, $NHCH_2CH_2NH_2$, NH-phenyl, piperazinyl, pyrrolidinyl or $CONR'_2$; O-(C_1-C_3)-alkyl optionally substituted with NR'_2, OR', CO_2R', $S(O_2)N(R')_2$, N=CH-$N(R')_2$, R^3, or $CONR'_2$; NR'_2; OCF_3; CF_3; NO_2; CO_2R'; CONHR'; R^3; OR^3; NHR^3; SR^3; $C(O)R^3$; $C(O)N(R')R^3$; $C(O)OR^3$; SR'; $S(O_2)N(R')_2$; SCF_3; N=CH-$N(R')_2$; or CN;

R' is selected from hydrogen, (C_1-C_3)-alkyl; (C_2-C_3)-alkenyl or alkynyl; phenyl or phenyl substituted with 1 to 3 substituents independently selected from halo, methoxy, cyano, nitro, amino, hydroxy, methyl or ethyl;

R^3 is selected from a 5-6 membered aromatic carbocyclic or heterocyclic ring system;

R^4 is (C_1-C_4)-alkyl optionally substituted with $N(R')_2$, OR', CO_2R', $CON(R')_2$, or $SO_2N(R^2)_2$; or a 5-6 membered carbocyclic or heterocyclic ring system optionally substituted with $N(R')_2$, OR', CO_2R', $CON(R')_2$, or $SO_2N(R^2)_2$;

X is selected from -S-, -O-, -$S(O_2)$-, -S(O)-, -$S(O_2)$-$N(R^2)$-, -$N(R^2)$-$S(O_2)$-, -$N(R^2)$-C(O)O-, -O-C(O)-$N(R^2)$, -C(O)-, -C(O)O-, -O-C(O)-, -C(O)-$N(R^2)$-, -$N(R^2)$-C(O)-, -$N(R^2)$-, -$C(R^2)_2$-, -$C(OR^2)_2$-, or -CH(OH)-;

each R is independently selected from hydrogen, -R^2, -$N(R^2)_2$, -OR^2, SR^2, -C(O)-$N(R^2)_2$, -$S(O_2)$-$N(R^2)_2$, or -C(O)-OR^2, wherein two adjacent R are optionally bound to one another and, together with each carbon to which they are respectively bound, form a 4-8 membered carbocyclic or heterocyclic ring;

R^2 is selected from hydrogen, (C_1-C_3)-alkyl, or (C_1-C_3)-alkenyl; wherein each (C_1-C_3)-alkyl or (C_1-C_3)-alkenyl is optionally substituted with -$N(R')_2$, -OR', SR', -C(O)-$N(R')_2$, -$S(O_2)$-$N(R')_2$, -C(O)-OR', or R^3;

E3

Y is C;

A is CR'; and

n is 1; wherein an aromatic heterocyclic ring system consists of 1-2 heteroatoms independently selected from N, O or S.

E4

sub F4

63. (Amended) A method of treating inflammatory diseases, autoimmune diseases, destructive bone disorders, infectious diseases, neurodegenerative diseases, reperfusion/ischemia in stroke, myocardial ischemia, renal ischemia, heart attacks, angiogenic disorders, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin-induced platelet aggregation or conditions associated with prostaglandin endoperoxide synthase-2 in a patient, said method comprising administering to said patient a composition according to claim 62.

E5

sub F5

65. (Amended) A method of treating inflammatory diseases, autoimmune diseases, destructive bone disorders, infectious diseases, neurodegenerative diseases, reperfusion/ischemia in stroke, myocardial ischemia, renal ischemia, heart attacks, angiogenic disorders, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin-induced platelet aggregation or conditions associated with prostaglandin endoperoxide synthase-2 in a patient, said method comprising administering to said patient a composition according to claim 64.

E6

sub F6

67. (Amended) A method of treating inflammatory diseases, autoimmune diseases, destructive bone disorders, infectious diseases, neurodegenerative diseases, reperfusion/ischemia in stroke, myocardial ischemia, renal ischemia, heart attacks, angiogenic disorders, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin-induced platelet aggregation or conditions associated with prostaglandin endoperoxide synthase-2 in a patient, said method comprising administering to said patient a composition according to claim 66.